Things Just Got a Little Brighter for Vivus
Most Popular - It seems Vivus Pharmaceuticals (VVUS) may have some important news coming. Two Vivus patent applications covering Qsymia appear to be in a condition for allowance … Continue Reading
Read nowAuthor Archives: Jake King
FDA Schedules the Relistor Advisory Committee Meeting
Long Ideas - On Tuesday afternoon at 2:30PM ET, Progenics (PGNX) and Salix Pharmaceuticals (SLXP) announced that an FDA advisory committee weighing the Supplemental New Drug Application for … Continue Reading
Read nowOncothyreon’s Failed Cancer Drug Moves Ahead in the Clinic
Most Popular - This note was sent to PropThink’s Premium subscribers on Wednesday September 25. On August 22, Mr. King spotlighted a recently in-licensed asset at Oncothyreon (ONTY), … Continue Reading
Read nowEvaluating Sunshine Heart’s Recent Capital Raise
Long Ideas - Last week, while most of PropThink’s research team was on vacation, Sunshine Heart (SSH) commenced a secondary offering that should net proceeds of approximately $37 … Continue Reading
Read nowLeaning Towards Favorable Outcomes from Endocyte’s Upcoming Events
Long Ideas - Targeted therapies are the oncologists’ precision tool in treating difficult cancers. Where early therapeutics like radiotherapy and chemotherapy tackle cancers by bombarding all rapidly dividing … Continue Reading
Read nowXenoPort’s Tecfidera-Me-Too Looks Good So Far, but the Next Steps are Unclear
Insights - After the bell Monday evening XenoPort (XNPT) released results from three early studies of XP23829, the company’s novel fumaric acid ester compound and a prodrug of monomethyl … Continue Reading
Read nowThe FDA Isn’t Pleased With MiMedx
Insights - On Wednesday shortly after the lunch hour, the FDA posted publicly a letter dated August 28 that was sent to MiMedx Group (MDXG), a developer … Continue Reading
Read now